Literature DB >> 20424433

Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases.

A Girolami1, E Allemand, I Bertozzi, N Candeo, S Marun, B Girolami.   

Abstract

The occurrence of thrombotic events in patients with congenital bleeding conditions has received considerable attention in recent years. The same is true for asymptomatic defects of factors of the contact phase of blood coagulation, mainly FXII. Anecdotal reports on thrombosis in patients with prekallikrein deficiency have occasionally been reported. These involved both arterial and venous thrombosis. The purpose of the present article is to analyze the stories and the clinical pictures of all 75 cases of prekallikrein deficiency published so far. Among these patients were 9 with thrombosis, 6 arterial (myocardial infarction and ischemic stroke) and 3 venous (deep vein thrombosis with or without pulmonary embolism). In 6 cases acquired thrombosis risk factors were present; in 2 cases no associated risk factors were present and in 1 case no information was supplied in this regard. One patient who presented both a stroke and a pulmonary embolism had a fatal outcome. The article clearly indicates that prekallikrein deficiency does not protect from thrombosis in spite of the severe in vitro coagulation defect. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424433     DOI: 10.1159/000313361

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  10 in total

1.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Authors:  Alexey S Revenko; Dacao Gao; Jeff R Crosby; Gourab Bhattacharjee; Chenguang Zhao; Chris May; David Gailani; Brett P Monia; A Robert MacLeod
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

2.  Prolonged Activated Clotting Time Immediately Prior to Open Cardiac Surgery.

Authors:  Sarah M Baker; Ashley Kiefer; Dominic S Carollo; Rajasekharan P Warrier
Journal:  Ochsner J       Date:  2018

3.  Severe Prekallikrein Deficiency Associated with Low Level of Factor XII: A Case Report.

Authors:  Massoumeh Shahbazi; Minoo Ahmadinejad; Shahnaz Fakhrzadegan
Journal:  Iran J Pathol       Date:  2021-05-09

4.  Isolated APTT prolongation-not always a bleeding risk in acute paediatric burns surgery.

Authors:  M Nizamoglu; K S Alexander; U Anwar; S Bhandari
Journal:  Eur J Plast Surg       Date:  2014-09-05

5.  Diagnostic Pearls and Clinical Implications of Prekallikrein Deficiency.

Authors:  Hassaan Yasin; Muhammad Omer Jamil; Lance A Williams Iii
Journal:  Cureus       Date:  2020-05-29

6.  The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c.1198G>T).

Authors:  Sohee Ryu; Ja Yoon Gu; Kyung Taek Hong; Doo Hee Han; Hyun Kyung Kim
Journal:  Ann Lab Med       Date:  2019-03       Impact factor: 3.464

7.  IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Authors:  Jason D Ferrone; Gourab Bhattacharjee; Alexey S Revenko; Thomas A Zanardi; Marshelle S Warren; Frederick J Derosier; Nicholas J Viney; Nguyen C Pham; Gwendolyn E Kaeser; Brenda F Baker; Eugene Schneider; Steven G Hughes; Brett P Monia; A Robert MacLeod
Journal:  Nucleic Acid Ther       Date:  2019-02-28       Impact factor: 5.486

8.  Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.

Authors:  Esteban Uribe Bojanini; Arturo Loaiza-Bonilla; Agustin Pimentel
Journal:  Case Rep Hematol       Date:  2012-08-16

9.  Increased Prevalence of Reported Cases of Congenital Prekallikrein Deficiency Among African Americans as Compared With the General Population of the United States.

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Bruno Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

10.  Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.

Authors:  Katherine J Kearney; Juliet Butler; Olga M Posada; Clare Wilson; Samantha Heal; Majid Ali; Lewis Hardy; Josefin Ahnström; David Gailani; Richard Foster; Emma Hethershaw; Colin Longstaff; Helen Philippou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.